Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea-Reference-Cited by-同舟云学术

Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea

Author:

Lee Hankil¹²³^ORCID,Cho Hyeonseok¹,Han Jung Woo⁴⁵,Kim Ah‐Young⁶,Park Seonyoung⁶,Lee Minjun⁶,Cho Sunghwa⁶,Baik Deborah¹,Kang Hye‐Young¹

Affiliation:

1. College of Pharmacy Yonsei Institute of Pharmaceutical Sciences Yonsei University Incheon South Korea

2. CONNECT‐AI Research Center Yonsei University College of Medicine Seoul South Korea

3. Institute of Health Services Research Yonsei University College of Medicine Seoul South Korea

4. Department of Pediatrics Yonsei University College of Medicine Yonsei University Health System Seoul South Korea

5. Department of Pediatric Hemato‐oncology Yonsei Cancer Center Yonsei University Health System Seoul South Korea

6. Department of Pharmaceutical Medicine and Regulatory Sciences Colleges of Medicine and Pharmacy Yonsei University Incheon South Korea

Funder

JW Pharmaceuticals

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

Reference43 articles.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献